Recombinant human serum albumin containing 3 copies of domain I, Has significant in vitro antioxidative capacity compared to the wild-type

Sadaharu Matsushita, Koji Nishi, Yasunori Iwao, Yu Ishima, Hiroshi Watanabe, Kazuaki Taguchi, Keishi Yamasaki, Toru Maruyama, Masaki Otagiri

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Human serum albumin (HSA), the most abundant protein in serum, functions as carrier of drugs and contributes to maintaining serum colloid osmotic pressure. We report herein on the preparation of a genetic recombinant HSA, in which domains II and III were changed to domain I (triple domain I; TDI). Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) results indicated that the purity of the TDI was equivalent to that of the wild type (WT). Both far- and near-UV circular dichroism (CD) spectra of the TDI showed that its structural characteristics were similar to the WT. Ligand binding capacity was examined by an ultrafiltration method using 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) and ketoprofen as markers for site I and site II, respectively. The binding capacity of TDI for both ligands was lower than that for the wild type. TDI significantly suppressed the oxidation of dihydrorhodamine 123 (DRD) by H2O2 compared to the WT. Our current results suggest that TDI has great potential for further development as HSA a product having antioxidative functions.

Original languageEnglish
Pages (from-to)1813-1817
Number of pages5
JournalBiological and Pharmaceutical Bulletin
Volume40
Issue number10
DOIs
Publication statusPublished - 2017 Jan 1
Externally publishedYes

Fingerprint

Serum Albumin
Ligands
Ketoprofen
Drug Carriers
Osmotic Pressure
Medical Genetics
Ultrafiltration
Colloids
Human Development
Circular Dichroism
Sodium Dodecyl Sulfate
Blood Proteins
Polyacrylamide Gel Electrophoresis
Serum
In Vitro Techniques
3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid
dihydrorhodamine 123

Keywords

  • Antioxidative property
  • Domain I
  • Human serum albumin
  • Ligand-binding

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Recombinant human serum albumin containing 3 copies of domain I, Has significant in vitro antioxidative capacity compared to the wild-type. / Matsushita, Sadaharu; Nishi, Koji; Iwao, Yasunori; Ishima, Yu; Watanabe, Hiroshi; Taguchi, Kazuaki; Yamasaki, Keishi; Maruyama, Toru; Otagiri, Masaki.

In: Biological and Pharmaceutical Bulletin, Vol. 40, No. 10, 01.01.2017, p. 1813-1817.

Research output: Contribution to journalArticle

Matsushita, S, Nishi, K, Iwao, Y, Ishima, Y, Watanabe, H, Taguchi, K, Yamasaki, K, Maruyama, T & Otagiri, M 2017, 'Recombinant human serum albumin containing 3 copies of domain I, Has significant in vitro antioxidative capacity compared to the wild-type', Biological and Pharmaceutical Bulletin, vol. 40, no. 10, pp. 1813-1817. https://doi.org/10.1248/bpb.b17-00528
Matsushita, Sadaharu ; Nishi, Koji ; Iwao, Yasunori ; Ishima, Yu ; Watanabe, Hiroshi ; Taguchi, Kazuaki ; Yamasaki, Keishi ; Maruyama, Toru ; Otagiri, Masaki. / Recombinant human serum albumin containing 3 copies of domain I, Has significant in vitro antioxidative capacity compared to the wild-type. In: Biological and Pharmaceutical Bulletin. 2017 ; Vol. 40, No. 10. pp. 1813-1817.
@article{85558d6e9611440caa95d046158cfabe,
title = "Recombinant human serum albumin containing 3 copies of domain I, Has significant in vitro antioxidative capacity compared to the wild-type",
abstract = "Human serum albumin (HSA), the most abundant protein in serum, functions as carrier of drugs and contributes to maintaining serum colloid osmotic pressure. We report herein on the preparation of a genetic recombinant HSA, in which domains II and III were changed to domain I (triple domain I; TDI). Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) results indicated that the purity of the TDI was equivalent to that of the wild type (WT). Both far- and near-UV circular dichroism (CD) spectra of the TDI showed that its structural characteristics were similar to the WT. Ligand binding capacity was examined by an ultrafiltration method using 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) and ketoprofen as markers for site I and site II, respectively. The binding capacity of TDI for both ligands was lower than that for the wild type. TDI significantly suppressed the oxidation of dihydrorhodamine 123 (DRD) by H2O2 compared to the WT. Our current results suggest that TDI has great potential for further development as HSA a product having antioxidative functions.",
keywords = "Antioxidative property, Domain I, Human serum albumin, Ligand-binding",
author = "Sadaharu Matsushita and Koji Nishi and Yasunori Iwao and Yu Ishima and Hiroshi Watanabe and Kazuaki Taguchi and Keishi Yamasaki and Toru Maruyama and Masaki Otagiri",
year = "2017",
month = "1",
day = "1",
doi = "10.1248/bpb.b17-00528",
language = "English",
volume = "40",
pages = "1813--1817",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "10",

}

TY - JOUR

T1 - Recombinant human serum albumin containing 3 copies of domain I, Has significant in vitro antioxidative capacity compared to the wild-type

AU - Matsushita, Sadaharu

AU - Nishi, Koji

AU - Iwao, Yasunori

AU - Ishima, Yu

AU - Watanabe, Hiroshi

AU - Taguchi, Kazuaki

AU - Yamasaki, Keishi

AU - Maruyama, Toru

AU - Otagiri, Masaki

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Human serum albumin (HSA), the most abundant protein in serum, functions as carrier of drugs and contributes to maintaining serum colloid osmotic pressure. We report herein on the preparation of a genetic recombinant HSA, in which domains II and III were changed to domain I (triple domain I; TDI). Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) results indicated that the purity of the TDI was equivalent to that of the wild type (WT). Both far- and near-UV circular dichroism (CD) spectra of the TDI showed that its structural characteristics were similar to the WT. Ligand binding capacity was examined by an ultrafiltration method using 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) and ketoprofen as markers for site I and site II, respectively. The binding capacity of TDI for both ligands was lower than that for the wild type. TDI significantly suppressed the oxidation of dihydrorhodamine 123 (DRD) by H2O2 compared to the WT. Our current results suggest that TDI has great potential for further development as HSA a product having antioxidative functions.

AB - Human serum albumin (HSA), the most abundant protein in serum, functions as carrier of drugs and contributes to maintaining serum colloid osmotic pressure. We report herein on the preparation of a genetic recombinant HSA, in which domains II and III were changed to domain I (triple domain I; TDI). Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) results indicated that the purity of the TDI was equivalent to that of the wild type (WT). Both far- and near-UV circular dichroism (CD) spectra of the TDI showed that its structural characteristics were similar to the WT. Ligand binding capacity was examined by an ultrafiltration method using 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) and ketoprofen as markers for site I and site II, respectively. The binding capacity of TDI for both ligands was lower than that for the wild type. TDI significantly suppressed the oxidation of dihydrorhodamine 123 (DRD) by H2O2 compared to the WT. Our current results suggest that TDI has great potential for further development as HSA a product having antioxidative functions.

KW - Antioxidative property

KW - Domain I

KW - Human serum albumin

KW - Ligand-binding

UR - http://www.scopus.com/inward/record.url?scp=85030774993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030774993&partnerID=8YFLogxK

U2 - 10.1248/bpb.b17-00528

DO - 10.1248/bpb.b17-00528

M3 - Article

VL - 40

SP - 1813

EP - 1817

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 10

ER -